Suspension of Bitstamp as a CF Constituent Exchange for two CF Digital Asset Index Family indices
The Administrator announces the suspension of Bitstamp as a CF Constituent Exchange for the CF UMA-Dollar Spot Rate (UMAUSD_RTI), and CF Injective-Dollar Spot Rate (INJUSD_RTI), effective May 19th, 2025.

The Administrator announces the suspension of Bitstamp as a CF Constituent Exchange for the following indices within the CF Digital Asset Index Family – Single Asset Series, effective May 19th, 2025:
- CF UMA-Dollar Spot Rate (UMAUSD_RTI)
- CF Injective-Dollar Spot Rate (INJUSD_RTI)
Rationale
The Administrator continuously monitors input data from Constituent Exchanges against the CF Constituent Exchange Criteria, to assess each venue's ongoing eligibility. Although benchmark input data are sourced from order books rather than executed trades, the Administrator has determined that persistently low trading activity on Bitstamp has negatively impacted the depth and representativeness of the order books from which data for the above indices are derived. As a result, Bitstamp will be suspended as a Constituent Exchange for the indices listed above. This suspension is indefinite.
Implementation Date
The suspension will take effect at approximately 11:00 a.m. London Time, on May 19th, 2025. The process has been conducted under the supervision of the CF Cryptocurrency Index Family Oversight Function.
Questions and complaints
For questions regarding this suspension, please contact: info@cfbenchmarks.com.
To submit a confidential complaint, please email: complaints@cfbenchmarks.com.
The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell any of the underlying instruments cited including but not limited to cryptoassets, financial instruments or any instruments that reference any index provided by CF Benchmarks Ltd. This communication is not intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. Please contact your financial adviser or professional before making an investment decision.